Premarket Movers Sept 28, 2026: KOD, GYGY, CLRO

KOD — Kodiak Sciences Inc. (+96.4%)

Kodiak Sciences is the standout premarket mover this morning, nearly doubling to $63.52 on volume of 4,557,902 shares — more than five times its 20-day average of 898,471. This is a classic binary-event gap: the stock had been widely flagged as a catalyst play, and the catalyst has now landed.

Why it's up: Kodiak Sciences released topline results from the DAYBREAK pivotal Phase 3 study of its wet age-related macular degeneration (wet AMD) treatments — Zenkuda and KSI-501 — this morning. Advfn reported that shares are rising after those results, consistent with the company's pre-announced presentation date of September 28. Wet AMD is a leading cause of vision loss in older adults, making a successful Phase 3 readout a potentially significant commercial milestone for a company this size.

The setup heading into this morning was cautious on the chart: RSI sat at just 38 — oversold territory — and the stock was trading 30.4% below its 52-week high. The MA stack was mixed, and StockSetups had assigned a conviction score of 47/100 with a C grade. In other words, the technicals alone were not screaming "buy" — this move is entirely catalyst-driven, not a breakout that had been building. That makes the post-open price action especially unpredictable.

Where KOD gets genuinely interesting is the short-side data. The stock carries a squeeze score of 100/100 — the maximum reading — with 10,780,926 shares short and a staggering 18.4 days to cover (meaning, at average volume, it would take short sellers more than 18 trading days to buy back their borrowed shares). When a heavily shorted stock gaps up sharply on a binary catalyst like clinical trial results, shorts are forced to buy to limit losses, which can amplify and extend the move well beyond what the news alone would justify. That dynamic is very likely playing a role in this morning's near-doubling. Short-volume was running at 77% in recent sessions, reinforcing the pressure.

A word of caution: binary clinical trial moves are among the most volatile events in the market. Stocks that gap up on Phase 3 results can fade sharply if investors who held through the risk sell into the news, or if the data is viewed as less convincing on closer reading. With the regular session not yet open, the opening price is uncertain, and the premarket level may not hold. The RS rating of 94 shows strong relative strength, but the smart-money score is only 30/100, and the largest disclosed stake is just 5.2%. Treat this as a high-risk, event-driven situation.

GYGY — Game Your Game Inc. (+73.4%)

Game Your Game is surging +73.4% to $1.27 premarket on massive volume of 55,410,247 shares — roughly 20x its 20-day average of 2,770,791. For a stock with a market cap of just $10.5 million, that volume is extraordinary and signals a crowd-driven, momentum-led move.

Why it's up: The clearest recent catalyst in the data is a TipRanks report from September 23 noting that Game Your Game launched the GameGolf KZN AI Platform — an AI-based product in the golf technology space. The company's recent 8-K filing (other event) on September 23 likely relates to this announcement. There is no additional web-research catalyst provided this morning beyond that product launch. Given the timing gap between the September 23 announcement and this morning's move, the specific trigger for today's spike is not fully explained by the available data, and this move should be treated as primarily momentum-driven.

The technical picture entering this morning was deeply distressed: RSI at 7 (severely oversold — a reading that low often indicates a stock in freefall or illiquid enough that a single burst of buying creates an outsized price swing), ADX at 43 (a strong trend, but a downtrend), and the stock sitting 95.4% below its 52-week high. Conviction was 0/100 with a D grade. There is virtually no short-squeeze component here — the squeeze score is 1/100, with only 303,134 shares short and 0.1 days to cover — so this is not a short-squeeze story.

The SEC filing history — four 424B3 resale prospectus filings since early September — is a yellow flag. These filings indicate that previously restricted shares are being registered for resale, which creates potential selling pressure. A stock in a steep downtrend, filing repeated resale prospectuses, that suddenly spikes 73% on very high volume is a pattern that has historically attracted momentum traders chasing a bounce rather than fundamental buyers. This is a high-risk, speculative name. Premarket volume does not guarantee the move holds once the regular session opens.

CLRO — ClearOne Inc. (+56.9%)

ClearOne is trading up +56.9% to $5.49 premarket on volume of 13,554,502 shares — approximately 604x its 20-day average of just 22,451. That extreme relative volume on a stock this thinly traded is a signal that something specific is driving attention, even if the picture is complicated.

Why it's up: The available data presents a mixed story. ClearOne's premarket setup includes an +8.8% gap at the prior close, suggesting some positive price action was already underway. However, today's available headlines — from StocksToTrade and Timothy Sykes — describe the stock as sliding on weak financials, which directly contradicts the direction of the premarket move. This mismatch between the headline narrative and the price action, combined with the extraordinary relative volume versus a tiny average, suggests this could be momentum trading or a short-term liquidity event rather than a clean fundamental catalyst. The S-1/A filing from September 4 relates to an IPO-adjacent registration, which may be drawing speculative interest.

The largest disclosed stake is 61.3% — a striking concentration that means the freely tradable float is extremely limited. A low float (meaning few shares available for public trading) means even modest buying can create outsized price swings in either direction. The squeeze score is only 25/100 with minimal short interest (24,903 shares, 0.5 days to cover), so a short squeeze is not the story here.

The technical setup heading into today was weak: RSI of 34, ADX of 18 (a low reading indicating no strong trend), mixed MA stack, and a trend-template score of just 1. Conviction was 35/100, grade D, with the stock 74.7% below its 52-week high. Headline-price divergence, concentrated ownership, razor-thin average volume, and weak technicals all argue for significant caution. Stocks with this profile can move violently in both directions within the same session.

MIMI — Mint Inc. Ltd. (+30.6%)

Mint Inc. is up +30.6% to $1.01 premarket on volume of 13,794,051 shares, roughly in line with its elevated 20-day average of 9,578,527 — suggesting this name has been actively traded recently. With a market cap of just $2.1 million, MIMI is a micro-cap operating in Consumer Discretionary.

Why it's up: No specific catalyst headline is available for this morning's move. The most recent filing activity consists of multiple 6-K reports (foreign private issuer event disclosures) through September, plus a Schedule 13G passive stake filing from early September. There is no press release, earnings report, or partnership announcement in the data. The catalyst is unclear, and this move appears to be momentum-driven, potentially tied to the recent high trading volume keeping the name on day-traders' radar.

One notable data point: the CEO, Chan Hoi Lung, purchased 211,879 shares worth approximately $638,000 back in May 2026 — a meaningful insider buy that may have attracted attention in momentum-trading communities over time. However, that purchase is several months old and is unlikely to be the direct trigger for today's move.

The technicals are bearish: a bearish engulfing candlestick pattern at the prior close, an RSI of 32, a fully bearish MA stack, and a trend-template score of 0. Conviction is 0/100, grade D, and the stock is 99.1% below its 52-week high — a stark reminder of how far this name has fallen. The squeeze score is 13/100 with minimal short interest. With a 71.6% free float, this isn't a tight-float situation either. All of this points to a speculative, low-conviction spike in a distressed stock. Premarket moves in names like this are notoriously difficult to trade profitably.

MEDS — DataMeds AI, Inc. (+25.7%)

DataMeds AI is up +25.7% to $3.96 premarket on 12,727,387 shares, slightly below its 20-day average of 14,595,334 — meaning today's move is happening on roughly normal volume for this name, which makes it relatively more orderly than the other movers on this list.

Why it's up: Yahoo Finance is reporting this morning that DataMeds AI and Tollo Health announced the launch of the "Health Lives Here" mobile application — a consumer-facing health platform. This is a concrete product launch catalyst. The company also recently announced a presentation at the 2026 National Telehealth and Virtual Care Summit (September 25), reinforcing its positioning as an AI-driven telehealth player.

This is the second time MEDS has appeared in a StockSetups premarket recap in September — it was featured in Premarket Movers September 16, 2026 and again in Premarket Movers September 17, 2026, underscoring how repeat volatility is common in small healthcare-tech names.

The technical picture is more nuanced than the others on this list: RSI is a neutral 53, and ADX at 55 signals a genuinely strong trend is in place — though direction matters. The prior-close candle is a bearish belt hold, which is a single-candle reversal warning signal. The stock is 86% below its 52-week high, and conviction is 0/100 with a D grade. One important risk flag: a bearish dilution-flagged 8-K was filed on September 16 — dilution (issuing new shares) is a common financing tool for micro-cap companies and directly reduces the value of existing shares. Short-sale restriction (SSR) is active, meaning regulators have placed a temporary restriction on aggressive short selling in this name, which can limit downside pressure but also signals prior volatility. The squeeze score is 21/100 — modest.

The "Health Lives Here" app launch is a legitimate, verifiable catalyst, but a $9.6M market-cap company co-launching a mobile app with an unspecified partner is a small news item. Trade the reality of the setup and the risk of follow-through carefully.

The bottom line

This morning's premarket movers span the full risk spectrum — from a genuine binary clinical trial catalyst (KOD) to momentum-driven micro-caps with no clear news driver (MIMI, GYGY). A few themes are worth keeping front of mind before the 9:30 AM ET open:

Chasing premarket spikes is high-risk. The prices you see before the open are set on lighter volume than the regular session. When the full market opens, institutional and retail sellers often hit the bid, and stocks that looked like they'd hold gains can give them back quickly. This is especially true for micro-caps and low-float names.

Short squeezes can amplify moves — but they can also unwind fast. KOD's squeeze score of 100/100 and 18.4 days to cover is the most significant squeeze setup on this list. When heavily shorted stocks gap on catalysts, forced short covering adds fuel to the fire — but once covering is done, that demand disappears. For more on how squeezes work, see [figure:short-interest].

Weak technicals don't mean a stock can't spike — but they do mean the move is harder to sustain. GYGY, MIMI, and CLRO all carry conviction scores of 35 or below, D grades, and deeply distressed chart setups. A spike in a broken stock is not the same as a breakout in a healthy one.

Do your own research and manage your risk. Nothing in this recap is a recommendation to buy or sell any security. These are some of the most volatile names trading in the US market this morning.

StockSetups scans the full ~12,300-stock US universe every premarket morning, detecting chart patterns, computing squeeze and conviction scores, and surfacing names like these before the open. Check back after the close for the full after-hours recap of how today's session plays out.